Terms: = Breast cancer AND MUC16, CA125, CA-125 AND Clinical Outcome
6 results:
1. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
2. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract] [Full Text] [Related]
3. ALDH1 expression correlates with favorable prognosis in ovarian cancers.
Chang B; Liu G; Xue F; Rosen DG; Xiao L; Wang X; Liu J
Mod Pathol; 2009 Jun; 22(6):817-23. PubMed ID: 19329942
[TBL] [Abstract] [Full Text] [Related]
4. Cerebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C; Tsavaris NB; Tsakonas G; Soukouli G; Gassiamis A; Mylonakis N; Karabelis A
Med Sci Monit; 2005 Aug; 11(8):CR398-401. PubMed ID: 16049383
[TBL] [Abstract] [Full Text] [Related]
5. Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C; Tsavaris NB; Soukouli G; Gouveris P; Tsakonas G; Katselis J; Alexopoulos H; Mylonakis N; Karabelis A
Med Oncol; 2005; 22(2):123-8. PubMed ID: 15965274
[TBL] [Abstract] [Full Text] [Related]
6. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract] [Full Text] [Related]
